The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyzna w wieku co najmniej 18 lat z potwierdzonym rakiem gruczołu krokowego
- •Ogólny stan zdrowia pozwalający na udział w badaniu i oczekiwana długość życia co najmniej 6 miesięcy
- •Przerzuty raka widoczne w badaniach obrazowych (CT, MRI lub scyntygrafia kostna)
- •Rak oporny na kastrację - choroba postępująca mimo leczenia hormonalnego, z niskim poziomem testosteronu
- •Wcześniejsze leczenie inhibitorem ścieżki receptora androgenu (abiraterone, apalutamide, darolutamide lub enzalutamide) przez co najmniej 12 tygodni z potwierdzonym progresem choroby
- •Postępująca choroba potwierdzona wzrostem PSA lub nowymi zmianami w badaniach obrazowych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (33)
Chao Family Comprehensive Cancer Centre
Orange, United States
Biogenix Molecular LLC
Miami, United States
United Theranostics
Glen Burnie, United States
XCancer Omaha
Omaha, United States
Columbia University Herbert Irving Comphrensive Cancer Center
New York, United States
University Hospital
Cleveland, United States
OHSU Knight Cancer Center
Portland, United States
Intermountain Health
Murray, United States
Intermountain Health
Salt Lake City, United States
Westmead Hospital
Sydney, Australia
Nepean Hospital
Sydney, Australia
Wollongong Hospital
Wollongong, Australia
Australian Prostate Centre
Melbourne, Australia
GenesisCare Murdoch
Perth, Australia
Mater Health Services Pty Ltd
Brisbane, Australia
GenesisCare Maitland
East Maitland, Australia
Austin Health
Heidelberg, Australia
GensisCare Cabrini
Malvern, Australia
GenesisCare North Adelaide
North Adelaide, Australia
Royal North Shore Hospital
Saint Leonards, Australia
GenesisCare Tugun
Tugun, Australia
INITIO Medical Group
Burnaby, Canada
Sunnybrook Research Institute
Toronto, Canada
Auckland City Hospital
Grafton, New Zealand
New Zealand Clinical Research - Christchurch
Christchurch, New Zealand
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
Ankara University Cebeci Hospital
Ankara, Turkey (Türkiye)
Hacettepe University Medical Faculty
Ankara, Turkey (Türkiye)
Maslak Acibadem Hospital
Istanbul, Turkey (Türkiye)
Charing Cross Hospital
London, United Kingdom
Royal Free Hospital
London, United Kingdom
University College London Hospitals
London, United Kingdom
Genesiscare Windsor
Windsor, United Kingdom
Trial contact
Lisa Sahadi
Mark Stein
PRINCIPAL_INVESTIGATOR
Westmead Hospital
Study Coordinator
Dr. Tania Moujaber
PRINCIPAL_INVESTIGATOR
Study Coordinator
Dr. Veronica Wong
PRINCIPAL_INVESTIGATOR
Dr. Gary Tincknell
PRINCIPAL_INVESTIGATOR
Prof Tony Costello
Prof. Tony Costello
PRINCIPAL_INVESTIGATOR
Study Coordinator
Dr. Aviral Singh
PRINCIPAL_INVESTIGATOR
Alice Hillman
Niara Oliveira
PRINCIPAL_INVESTIGATOR
Kristy Atherton
Sangeetha Ramanujan
PRINCIPAL_INVESTIGATOR
Michelle Starmans
Mario Guerrieri
PRINCIPAL_INVESTIGATOR
Geetanjali Rangnekar
Tony Michele
PRINCIPAL_INVESTIGATOR
Sally McCowatt
Alexander Guminski
PRINCIPAL_INVESTIGATOR
Kristy Longhurst
Sagar Ramani
PRINCIPAL_INVESTIGATOR
Philip Cohen
Urban Emmenegger
Urban Emmenegger
PRINCIPAL_INVESTIGATOR
Sergei Bendrikovskii
Simon Fu
PRINCIPAL_INVESTIGATOR
Anthony Rahman
PRINCIPAL_INVESTIGATOR
Can Abdan
Samet Taştan
Elif Özdemir
PRINCIPAL_INVESTIGATOR
Özlem Üstündağ
Yüksel Ürün
Yuksel Urun
PRINCIPAL_INVESTIGATOR
Eda Karabulut
Murat Bozkurt
Murat Bozkurt
PRINCIPAL_INVESTIGATOR
Doğukan Danışmant
Tevfik F Cermik
PRINCIPAL_INVESTIGATOR
Amalia Saucan
Naveed Sarwar
PRINCIPAL_INVESTIGATOR
Hannah Powell
Mark Prentice
PRINCIPAL_INVESTIGATOR
GU Research
Ursula McGovern
PRINCIPAL_INVESTIGATOR
Nicola Dallas
Nicola Dallas
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.